» Articles » PMID: 29556417

Identification of Monosodium Urate Crystal Deposits in Patients with Asymptomatic Hyperuricemia Using Dual-energy CT

Overview
Journal RMD Open
Specialty Rheumatology
Date 2018 Mar 21
PMID 29556417
Citations 15
Authors
Affiliations
Soon will be listed here.
Abstract

Objectives: Dual-energy CT (DECT) scan is a sensitive and specific tool used to visualise and quantify monosodium urate (MSU) crystal deposits in the joints. Few studies have examined MSU crystal deposits in patients with asymptomatic hyperuricemia (ie, hyperuricemia in the absence of gout) using DECT.

Methods: We conducted a prospective, non-interventional cross-sectional study to detect MSU crystal deposits on DECT scans among patients with asymptomatic hyperuricemia. We also examined patient factors associated with subclinical MSU crystal deposits. Out of 130 subjects aged ≥40 years with metabolic syndrome screened for serum uric acid (sUA) levels ≥6.5 mg/dL, 46 underwent a foot/ankle DECT scan.

Results: The mean age of the study participants was 62 (±8) years, 41% were men and the mean sUA level was 7.8 (±1.0) mg/dL. Seven (15%) of 46 patients had MSU crystal deposits on DECT with a mean total volume of 0.13 (±0.14) cm. In the univariable logistic regression analysis, older age had a significant association with presence of MSU crystal deposits (OR 1.20, 95% CI 1.03 to 1.39), but sUA did not (OR 1.36, 95% CI 0.63 to 2.95). In the univariable analysis, sUA levels showed a trend towards a modest linear association (β=0.11, P=0.09) with total volume of MSU crystal deposits.

Conclusions: Fifteen per cent of patients with asymptomatic hyperuricemia had subclinical MSU crystal deposits on foot/ankle DECT scans. Older age, but not sUA, was significantly associated with presence of subclinical MSU crystal deposits among patients with asymptomatic hyperuricemia. Clinical significance of these subclinical MSU crystal deposits needs to be determined.

Citing Articles

The comprehensive role of dual-energy CT in gout as an advanced diagnostic innovation.

Fukuda T, Subramanian M, Noda K, Kumeta S, Mori H, Ikeda N Skeletal Radiol. 2024; .

PMID: 39690304 DOI: 10.1007/s00256-024-04856-4.


Plasma and Urinary Metabolomic Analysis of Gout and Asymptomatic Hyperuricemia and Profiling of Potential Biomarkers: A Pilot Study.

Ohashi Y, Ooyama H, Makinoshima H, Takada T, Matsuo H, Ichida K Biomedicines. 2024; 12(2).

PMID: 38397902 PMC: 10887286. DOI: 10.3390/biomedicines12020300.


2023 EULAR recommendations on imaging in diagnosis and management of crystal-induced arthropathies in clinical practice.

Mandl P, DAgostino M, Navarro-Compan V, Gessl I, Sakellariou G, Abhishek A Ann Rheum Dis. 2024; 83(6):752-759.

PMID: 38320811 PMC: 11103298. DOI: 10.1136/ard-2023-224771.


Burden and distribution of monosodium urate deposition in patients with hyperuricemia and gout: a cross-sectional Chinese population-based dual-energy CT study.

Zhang X, Tang C, Zhou F, Lin P, Yin C, Gao Q Quant Imaging Med Surg. 2023; 13(7):4380-4391.

PMID: 37456310 PMC: 10347306. DOI: 10.21037/qims-22-1208.


Recent progress and perspectives on the relationship between hyperuricemia and periodontitis.

Hou W, Xia X, Li Y, Lv H, Liu J, Li X Front Immunol. 2022; 13:995582.

PMID: 36466813 PMC: 9708725. DOI: 10.3389/fimmu.2022.995582.


References
1.
Campion E, Glynn R, DeLabry L . Asymptomatic hyperuricemia. Risks and consequences in the Normative Aging Study. Am J Med. 1987; 82(3):421-6. DOI: 10.1016/0002-9343(87)90441-4. View

2.
Petsch C, Araujo E, Englbrecht M, Bayat S, Cavallaro A, Hueber A . Prevalence of monosodium urate deposits in a population of rheumatoid arthritis patients with hyperuricemia. Semin Arthritis Rheum. 2016; 45(6):663-8. DOI: 10.1016/j.semarthrit.2015.11.014. View

3.
Alberti K, Zimmet P . Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. Diabet Med. 1998; 15(7):539-53. DOI: 10.1002/(SICI)1096-9136(199807)15:7<539::AID-DIA668>3.0.CO;2-S. View

4.
Bongartz T, Glazebrook K, Kavros S, Murthy N, Merry S, Franz 3rd W . Dual-energy CT for the diagnosis of gout: an accuracy and diagnostic yield study. Ann Rheum Dis. 2014; 74(6):1072-7. PMC: 4431329. DOI: 10.1136/annrheumdis-2013-205095. View

5.
Khanna D, FitzGerald J, Khanna P, Bae S, Singh M, Neogi T . 2012 American College of Rheumatology guidelines for management of gout. Part 1: systematic nonpharmacologic and pharmacologic therapeutic approaches to hyperuricemia. Arthritis Care Res (Hoboken). 2012; 64(10):1431-46. PMC: 3683400. DOI: 10.1002/acr.21772. View